Sovaldi price worries states

Share this article:

Gilead's hepatitis C drug Sovaldi is giving Medicaid and private insurers a headache. Reuters reports that several insurers are talking with state agencies about how to handle Medicaid payments for a treatment that costs around $84,000 per person.

Reuters notes that this can also be just a starting price and that “many doctors are requesting a $150,000 combination of Sovaldi (sofosbuvir) and Olysio (simeprevir).”

This too, is a starting point of sorts: Harvard Medical School's Camilla Graham told Reuters that a cumulative number would probably hover around the $200 billion mark to treat two-thirds of hepatitis C patients at around $100,000 each.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.